226 related articles for article (PubMed ID: 11038265)
21. Pneumococcal vaccine for asthma.
Sheikh A; Alves B; Dhami S
Cochrane Database Syst Rev; 2001; 2002(3):CD002165. PubMed ID: 11687018
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials.
Fine MJ; Smith MA; Carson CA; Meffe F; Sankey SS; Weissfeld LA; Detsky AS; Kapoor WN
Arch Intern Med; 1994 Dec 12-26; 154(23):2666-77. PubMed ID: 7993150
[TBL] [Abstract][Full Text] [Related]
23. Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
Dunne EM; Cilloniz C; von Mollendorf C; Lewnard J; Grant LR; Slack MPE; Jodar L; Theilacker C; Gessner BD
Arch Bronconeumol; 2023 Mar; 59(3):157-164. PubMed ID: 36681604
[TBL] [Abstract][Full Text] [Related]
24. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
Fortanier AC; Venekamp RP; Boonacker CW; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
Cochrane Database Syst Rev; 2019 May; 5(5):CD001480. PubMed ID: 31135969
[TBL] [Abstract][Full Text] [Related]
25. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.
Vila-Córcoles A; Ochoa-Gondar O; Llor C; Hospital I; Rodríguez T; Gómez A
Eur Respir J; 2005 Dec; 26(6):1086-91. PubMed ID: 16319340
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.
Falkenhorst G; Remschmidt C; Harder T; Hummers-Pradier E; Wichmann O; Bogdan C
PLoS One; 2017; 12(1):e0169368. PubMed ID: 28061505
[TBL] [Abstract][Full Text] [Related]
27. Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines.
Principi N; Esposito S
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28029140
[TBL] [Abstract][Full Text] [Related]
28. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.
Vila-Corcoles A; Salsench E; Rodriguez-Blanco T; Ochoa-Gondar O; de Diego C; Valdivieso A; Hospital I; Gomez-Bertomeu F; Raga X
Vaccine; 2009 Mar; 27(10):1504-10. PubMed ID: 19171174
[TBL] [Abstract][Full Text] [Related]
29. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
[TBL] [Abstract][Full Text] [Related]
30. Pneumococcal vaccines for sickle cell disease.
Davies EG; Riddington C; Lottenberg R; Dower N
Cochrane Database Syst Rev; 2004; (1):CD003885. PubMed ID: 14974042
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of pneumococcal vaccination in adults: a meta-analysis.
Huss A; Scott P; Stuck AE; Trotter C; Egger M
CMAJ; 2009 Jan; 180(1):48-58. PubMed ID: 19124790
[TBL] [Abstract][Full Text] [Related]
32. Pneumococcal vaccines for preventing otitis media.
Straetemans M; Sanders EA; Veenhoven RH; Schilder AG; Damoiseaux RA; Zielhuis GA
Cochrane Database Syst Rev; 2004; (1):CD001480. PubMed ID: 14973970
[TBL] [Abstract][Full Text] [Related]
33. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
Mangtani P; Roberts JA; Hall AJ; Cutts FT
Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly - Selection of controls in a case-control study.
Kondo K; Suzuki K; Washio M; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2017 Aug; 35(36):4806-4810. PubMed ID: 28818473
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a large-scale retrospective cohort study.
Ansaldi F; Turello V; Lai P; Bastone G; De Luca S; Rosselli R; Durando P; Sticchi L; Gasparini R; Delfino E; Icardi G
J Int Med Res; 2005; 33(5):490-500. PubMed ID: 16222881
[TBL] [Abstract][Full Text] [Related]
36. Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study.
Vila-Corcoles A; Ochoa-Gondar O; de Diego C; Satue E; Aragón M; Vila-Rovira A; Gomez-Bertomeu F; Magarolas R; Figuerola-Massana E; Raga X; Perez MO; Ballester F
BMC Infect Dis; 2018 Apr; 18(1):196. PubMed ID: 29699550
[TBL] [Abstract][Full Text] [Related]
37. Vaccines to Prevent Pneumococcal Community-Acquired Pneumonia.
van Werkhoven CH; Huijts SM
Clin Chest Med; 2018 Dec; 39(4):733-752. PubMed ID: 30390745
[TBL] [Abstract][Full Text] [Related]
38. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses.
Melegaro A; Edmunds WJ
Eur J Epidemiol; 2004; 19(4):353-63. PubMed ID: 15180106
[TBL] [Abstract][Full Text] [Related]
39. Impact of pneumococcal vaccination on morbidity and mortality of geriatric patients: a case-controlled study.
Wagner C; Popp W; Posch M; Vlasich C; Rosenberger-Spitzy A
Gerontology; 2003; 49(4):246-50. PubMed ID: 12792160
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
